New adjuvants for human vaccines
Authors:
- Ennio De GregorioEGEnnio De Gregorio
- Nicholas M ValianteNVNicholas M Valiante
- Rino RappuoliRRRino Rappuoli
- 1 June 2010
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 22 (3) , 411-416
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccineProceedings of the National Academy of Sciences, 2009
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Mechanism of action of clinically approved adjuvantsCurrent Opinion in Immunology, 2009
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeNew England Journal of Medicine, 2008
- Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccinesProceedings of the National Academy of Sciences, 2008
- Molecular and cellular signatures of human vaccine adjuvantsProceedings of the National Academy of Sciences, 2008
- The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activityEuropean Journal of Immunology, 2008
- Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNANature, 2008
- Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingProceedings of the National Academy of Sciences, 2008